Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S76-S93
DOI: 10.3350/cmh.2024.0438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Andrea Caddeo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Precision Medicine, Fatty Liver. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial disease and becoming the leading cause of liver-related morbidity and mortality. MASLD spans from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may progress to cirrhosis and hepatocellular carcinoma (HCC). Genetic, metabolic, and environmental factors strongly contribute to the heterogeneity of MASLD. Lifestyle intervention and weight loss represent a viable treatment for MASLD. Moreover, Resmetirom, a thyroid hormone beta receptor agonist, has recently been approved for MASLD treatment. However, most individuals treated did not respond to this therapeutic, suggesting the need for a more tailored approach to treat MASLD. Oligonucleotide-based therapies, namely small-interfering RNA (siRNA) and antisense oligonucleotide (ASO), have been recently developed to tackle MASLD by reducing the expression of genes influencing MASH progression, such as PNPLA3 and HSD17B13. Here, we review the latest progress made in the synthesis and development of oligonucleotide-based agents targeting genetic determinants of MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy.
- Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
- Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
- Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Medicine, Endocrinology (H7) Karolinska Institute and Hospital, Huddinge, Stockholm, Sweden.
Zitieren
APA
Caddeo, A., & Romeo, S. (2025). Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clinical and Molecular Hepatology, 31(Suppl), S76-S93. https://doi.org/10.3350/cmh.2024.0438
Vancouver
Caddeo A, Romeo S. Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(Suppl):S76-S93. doi:10.3350/cmh.2024.0438
BibTeX
@article{Caddeo2025,
author = {Caddeo, Andrea and Romeo, Stefano},
title = {Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {Suppl},
pages = {S76--S93},
doi = {10.3350/cmh.2024.0438}
}
EUVIMED